Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers

• Published in: Molecular therapy Vol. 24; no. 8; pp. 1492 - 1501
• Main Authors: Downs-Canner, Stephanie, Guo, Zong Sheng, Ravindranathan, Roshni, Breitbach, Caroline J, O'Malley, Mark E, Jones, Heather L, Moon, Anne, McCart, Judith Andrea, Shuai, Yongli, Zeh, Herbert J, Bartlett, David L
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2016; Elsevier Limited; Nature Publishing Group
• Subjects: Adult; Aged; Antibodies, Viral - immunology; Clinical trials; Combined Modality Therapy; Cytokines - metabolism; Drug dosages; FDA approval; Female; Genes; Genetic Therapy; Genetic Vectors - administration & dosage; Genetic Vectors - adverse effects; Genetic Vectors - genetics; Genetic Vectors - pharmacokinetics; Humans; Inflammation Mediators; Kinases; Liver cancer; Male; Melanoma; Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms - diagnosis; Neoplasms - genetics; Neoplasms - mortality; Neoplasms - therapy; Oncolytic Virotherapy - adverse effects; Oncolytic Virotherapy - methods; Oncolytic Viruses - genetics; Oncolytic Viruses - immunology; Original; Patients; Poxviridae - genetics; Poxviridae - immunology; Poxvirus; Retreatment; Smallpox; Toxicity; Treatment Outcome; Uric acid; Vaccinia virus; Viral infections; Viruses; United States > US; Pittsburgh Pennsylvania

We have conducted a phase 1 study of intravenous vvDD, a Western Reserve strain oncolytic vaccinia virus, on 11 patients with standard treatment-refractory advanced colorectal or other solid cancers. The primary endpoints were maximum tolerated dose and associated toxicity while secondary endpoints...